Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis

R Phillip Dellinger

doi:10.1186/cc3991

Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis

Crit Care. 2006 Feb;10(1):114. doi: 10.1186/cc3991.

Author

R Phillip Dellinger¹

Affiliation

¹ Section of Critical Care Medicine, Cooper University Hospital, One Cooper Plaza, Camden, NJ 08103, USA. [email protected]

PMID: 16542472
PMCID: PMC1550791
DOI: 10.1186/cc3991

Abstract

The PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial demonstrated a 6.1% absolute decrease in mortality with a p value of 0.005. Despite the impressive results of this trial, criticism of the study has targeted various aspects of design, analysis and interpretation. Additional studies of recombinant activated protein C (rhAPC) have added to our understanding about this drug and to controversy as well. So how do we deal with rhAPC use in our clinical practice?

Publication types

Review

MeSH terms

Humans
Protein C / therapeutic use*
Randomized Controlled Trials as Topic / mortality*
Recombinant Proteins / therapeutic use
Risk Factors
Systemic Inflammatory Response Syndrome / drug therapy
Systemic Inflammatory Response Syndrome / mortality

Substances

Protein C
Recombinant Proteins